Skip to main content
Journal cover image

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.

Publication ,  Journal Article
Nasrallah, HA; Meyer, JM; Goff, DC; McEvoy, JP; Davis, SM; Stroup, TS; Lieberman, JA
Published in: Schizophr Res
September 2006

UNLABELLED: Persons diagnosed with schizophrenia have higher morbidity and mortality rates from cardiovascular disease, yet often have limited access to appropriate primary care screening or treatment. Metabolic disorders such as diabetes, hyperlipidemia and hypertension are highly prevalent in populations with schizophrenia, exceeding 50% in some studies; however, there have been few published studies on treatment rates among schizophrenia patients screened for these disorders. METHODS: Using the baseline data from subjects (N=1460) recruited into the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, we examined the point prevalence of diabetes, hyperlipidemia and hypertension treatment at the time of enrollment for the entire cohort and those with fasting laboratory values obtained 8 or more hours since last meal. RESULTS: Rates of non-treatment ranged from 30.2% for diabetes, to 62.4% for hypertension, and 88.0% for dyslipidemia. Nonwhite men were more likely to be treated for DM and dyslipidemia than nonwhite women. CONCLUSIONS: These data indicate the high likelihood that metabolic disorders are untreated in patients with schizophrenia, with particularly high rates of non-treatment for hypertension and dyslipidemia. Nonwhite women may be especially vulnerable to undertreatment of dyslipidemia and diabetes compared to nonwhite men. The findings here support the need for increased attention to basic monitoring and treatment of cardiovascular risk factors in this vulnerable and often underserved psychiatric population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Schizophr Res

DOI

ISSN

0920-9964

Publication Date

September 2006

Volume

86

Issue

1-3

Start / End Page

15 / 22

Location

Netherlands

Related Subject Headings

  • Schizophrenia
  • Risk Factors
  • Psychiatry
  • Prevalence
  • Male
  • Hypertension
  • Humans
  • Female
  • Dyslipidemias
  • Diabetes Mellitus
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., & Lieberman, J. A. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res, 86(1–3), 15–22. https://doi.org/10.1016/j.schres.2006.06.026
Nasrallah, Henry A., Jonathan M. Meyer, Donald C. Goff, Joseph P. McEvoy, Sonia M. Davis, T Scott Stroup, and Jeffrey A. Lieberman. “Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.Schizophr Res 86, no. 1–3 (September 2006): 15–22. https://doi.org/10.1016/j.schres.2006.06.026.
Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006 Sep;86(1–3):15–22.
Nasrallah, Henry A., et al. “Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.Schizophr Res, vol. 86, no. 1–3, Sept. 2006, pp. 15–22. Pubmed, doi:10.1016/j.schres.2006.06.026.
Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006 Sep;86(1–3):15–22.
Journal cover image

Published In

Schizophr Res

DOI

ISSN

0920-9964

Publication Date

September 2006

Volume

86

Issue

1-3

Start / End Page

15 / 22

Location

Netherlands

Related Subject Headings

  • Schizophrenia
  • Risk Factors
  • Psychiatry
  • Prevalence
  • Male
  • Hypertension
  • Humans
  • Female
  • Dyslipidemias
  • Diabetes Mellitus